Previous 10 | Next 10 |
2024-04-17 09:26:31 ET More on CVS Health CVS Health: Seizing Opportunity Amid Recent Declines CVS Health: Good Management Is Keeping Their Promises CVS Health: Here Comes The Floor - Inherent Undervaluation Triggers Great Upside Potential Dividend Roundup: P...
2024-04-16 18:22:06 ET More on Johnson & Johnson, Teva Pharmaceutical, etc. Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript Johnson & Johnson 2024 Q1 - Results - Earnings Call Presentation Johnson & Johnson: Doubling Down On This 2024 Dog Of ...
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnso...
2024-04-16 12:54:17 ET More on AbbVie AbbVie: Great To Be Proven Wrong - Still Not A Buy AbbVie: Bulletproof Fundamentals AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% AbbVie working with FDA after reports of fake Botox versions ...
Almost 80% of patients with Huntington's disease (HD) chorea were able to achieve optimal dosing within four weeks with the 4-week Titration Kit in final START study results START study results further support real-world effectiveness, safety, adherence and patient satisfaction with the 4...
2024-04-13 10:52:04 ET More on AbbVie, Amgen, etc. AbbVie: Bulletproof Fundamentals AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% UnitedHealth Q1 2024 Earnings Preview: Headwinds Not Enough To Derail This Juggernaut GLP-1s benefit Park...
2024-04-11 11:12:32 ET More on Pfizer, Teva, etc. Teva Pharmaceutical Industries: Potential Outweighs Concerns Pfizer: Attractive Valuation And A Strong Pipeline Mitigate Patent Cliff Concerns Pfizer Inc. (PFE) Leerink Partners Global Biopharma Conference 2024 - (Tra...
2024-04-11 08:59:30 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries: Potential Outweighs Concerns Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities Teva Pharmaceutical: I Need To See Top-Line Growth Return Before Starting A Pos...
AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile Teva Pharmaceuticals, a U.S. affil...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2024 financial results on Wednesday, May 8, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emerg...
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...